These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 33648947)

  • 1. Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy.
    Leone RD; Powell JD
    Cancer Immunol Res; 2021 Mar; 9(3):255-260. PubMed ID: 33648947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NF-κB in the New Era of Cancer Therapy.
    Eluard B; Thieblemont C; Baud V
    Trends Cancer; 2020 Aug; 6(8):677-687. PubMed ID: 32409139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.
    Maes K; Mondino A; Lasarte JJ; Agirre X; Vanderkerken K; Prosper F; Breckpot K
    Front Immunol; 2021; 12():652160. PubMed ID: 33859645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors.
    Grosser R; Cherkassky L; Chintala N; Adusumilli PS
    Cancer Cell; 2019 Nov; 36(5):471-482. PubMed ID: 31715131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-G/LILRBs: A Cancer Immunotherapy Challenge.
    Carosella ED; Gregori S; Tronik-Le Roux D
    Trends Cancer; 2021 May; 7(5):389-392. PubMed ID: 33563576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting myeloid-derived suppressive cells in the tumor microenvironment to enhance the efficacy of cancer immunotherapy.
    Huo S; Liu L; Li Q; Wang J
    Discov Med; 2020; 30(161):119-128. PubMed ID: 33593480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape.
    Rodriguez-Garcia A; Palazon A; Noguera-Ortega E; Powell DJ; Guedan S
    Front Immunol; 2020; 11():1109. PubMed ID: 32625204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies.
    Zhang F; Stephan SB; Ene CI; Smith TT; Holland EC; Stephan MT
    Cancer Res; 2018 Jul; 78(13):3718-3730. PubMed ID: 29760047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.
    Satapathy BP; Sheoran P; Yadav R; Chettri D; Sonowal D; Dash CP; Dhaka P; Uttam V; Yadav R; Jain M; Jain A
    Front Immunol; 2024; 15():1389971. PubMed ID: 38799440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
    Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic reprogramming of terminally exhausted CD8
    Guo Y; Xie YQ; Gao M; Zhao Y; Franco F; Wenes M; Siddiqui I; Bevilacqua A; Wang H; Yang H; Feng B; Xie X; Sabatel CM; Tschumi B; Chaiboonchoe A; Wang Y; Li W; Xiao W; Held W; Romero P; Ho PC; Tang L
    Nat Immunol; 2021 Jun; 22(6):746-756. PubMed ID: 34031618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
    Carnevalli LS; Ghadially H; Barry ST
    Front Immunol; 2021; 12():633685. PubMed ID: 33953710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunometabolism: A 'Hot' Switch for 'Cold' Pediatric Solid Tumors.
    Xiao L; Yeung H; Haber M; Norris MD; Somers K
    Trends Cancer; 2021 Aug; 7(8):751-777. PubMed ID: 34183305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Bionanomaterials in Tumor Immune Microenvironment Therapy.
    Wang J; Bao Y; Yao Y
    J Immunol Res; 2021; 2021():6663035. PubMed ID: 33628850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Targeting Effect of Cetuximab Combined with PD-L1 Blockade against EGFR-Expressing Tumors in a Tailored CD16-CAR T-Cell Reporter System.
    Li Y; Gao Q; Liu H; Lin S; Chen H; Ding R; Gu Y; Chao CC; Dong X
    Cancer Invest; 2021 Apr; 39(4):285-296. PubMed ID: 33646061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy.
    Pellegrino M; Del Bufalo F; De Angelis B; Quintarelli C; Caruana I; de Billy E
    Cells; 2020 Dec; 10(1):. PubMed ID: 33374128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell exhaustion in human cancers.
    Kang K; Lin X; Chen P; Liu H; Liu F; Xiong W; Li G; Yi M; Li X; Wang H; Xiang B
    Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189162. PubMed ID: 39089484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From antibodies to living drugs: Quo vadis cancer immunotherapy?
    Szöőr Á; Szöllősi J; Vereb G
    Biol Futur; 2021 Mar; 72(1):85-99. PubMed ID: 34554498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.